The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Hepatitis B Therapeutic Drug Market Research Report 2025
Synopsis
Treatment for chronic hepatitis B may include: Antiviral medications. Several antiviral medications — including entecavir (Baraclude), tenofovir (Viread), lamivudine (Epivir), adefovir (Hepsera) and telbivudine (Tyzeka) — can help fight the virus and slow its ability to damage your liver.
The global Hepatitis B Therapeutic Drug market was valued at US$ 2157 million in 2023 and is anticipated to reach US$ 3242.7 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hepatitis B Therapeutic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis B Therapeutic Drug.
Report Scope
The Hepatitis B Therapeutic Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis B Therapeutic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis B Therapeutic Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Bristol-Myers Squibb
Mitsubishi Tanabe Pharma
Johnson & Johnson
Roche
Gilead Sciences
Merck & Co. Inc.
Novartis
AbbVie
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis B Therapeutic Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Treatment for chronic hepatitis B may include: Antiviral medications. Several antiviral medications — including entecavir (Baraclude), tenofovir (Viread), lamivudine (Epivir), adefovir (Hepsera) and telbivudine (Tyzeka) — can help fight the virus and slow its ability to damage your liver.
The global Hepatitis B Therapeutic Drug market was valued at US$ 2157 million in 2023 and is anticipated to reach US$ 3242.7 million by 2030, witnessing a CAGR of 6.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Hepatitis B Therapeutic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hepatitis B Therapeutic Drug.
Report Scope
The Hepatitis B Therapeutic Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Hepatitis B Therapeutic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Hepatitis B Therapeutic Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Bristol-Myers Squibb
Mitsubishi Tanabe Pharma
Johnson & Johnson
Roche
Gilead Sciences
Merck & Co. Inc.
Novartis
AbbVie
Segment by Type
Entecavir
Tenofovir
Lamivudine
Adefovir
Telbivudine
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hepatitis B Therapeutic Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Hepatitis B Therapeutic Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Entecavir
1.2.3 Tenofovir
1.2.4 Lamivudine
1.2.5 Adefovir
1.2.6 Telbivudine
1.2.7 Others
1.3 Market by Application
1.3.1 Global Hepatitis B Therapeutic Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies & Drug Stores
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Hepatitis B Therapeutic Drug Market Perspective (2019-2030)
2.2 Hepatitis B Therapeutic Drug Growth Trends by Region
2.2.1 Global Hepatitis B Therapeutic Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Hepatitis B Therapeutic Drug Historic Market Size by Region (2019-2024)
2.2.3 Hepatitis B Therapeutic Drug Forecasted Market Size by Region (2025-2030)
2.3 Hepatitis B Therapeutic Drug Market Dynamics
2.3.1 Hepatitis B Therapeutic Drug Industry Trends
2.3.2 Hepatitis B Therapeutic Drug Market Drivers
2.3.3 Hepatitis B Therapeutic Drug Market Challenges
2.3.4 Hepatitis B Therapeutic Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Hepatitis B Therapeutic Drug Players by Revenue
3.1.1 Global Top Hepatitis B Therapeutic Drug Players by Revenue (2019-2024)
3.1.2 Global Hepatitis B Therapeutic Drug Revenue Market Share by Players (2019-2024)
3.2 Global Hepatitis B Therapeutic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hepatitis B Therapeutic Drug Revenue
3.4 Global Hepatitis B Therapeutic Drug Market Concentration Ratio
3.4.1 Global Hepatitis B Therapeutic Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Hepatitis B Therapeutic Drug Revenue in 2023
3.5 Hepatitis B Therapeutic Drug Key Players Head office and Area Served
3.6 Key Players Hepatitis B Therapeutic Drug Product Solution and Service
3.7 Date of Enter into Hepatitis B Therapeutic Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Hepatitis B Therapeutic Drug Breakdown Data by Type
4.1 Global Hepatitis B Therapeutic Drug Historic Market Size by Type (2019-2024)
4.2 Global Hepatitis B Therapeutic Drug Forecasted Market Size by Type (2025-2030)
5 Hepatitis B Therapeutic Drug Breakdown Data by Application
5.1 Global Hepatitis B Therapeutic Drug Historic Market Size by Application (2019-2024)
5.2 Global Hepatitis B Therapeutic Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Hepatitis B Therapeutic Drug Market Size (2019-2030)
6.2 North America Hepatitis B Therapeutic Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Hepatitis B Therapeutic Drug Market Size by Country (2019-2024)
6.4 North America Hepatitis B Therapeutic Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Hepatitis B Therapeutic Drug Market Size (2019-2030)
7.2 Europe Hepatitis B Therapeutic Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Hepatitis B Therapeutic Drug Market Size by Country (2019-2024)
7.4 Europe Hepatitis B Therapeutic Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Hepatitis B Therapeutic Drug Market Size (2019-2030)
8.2 Asia-Pacific Hepatitis B Therapeutic Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Hepatitis B Therapeutic Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Hepatitis B Therapeutic Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Hepatitis B Therapeutic Drug Market Size (2019-2030)
9.2 Latin America Hepatitis B Therapeutic Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Hepatitis B Therapeutic Drug Market Size by Country (2019-2024)
9.4 Latin America Hepatitis B Therapeutic Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Hepatitis B Therapeutic Drug Market Size (2019-2030)
10.2 Middle East & Africa Hepatitis B Therapeutic Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Hepatitis B Therapeutic Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Hepatitis B Therapeutic Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Detail
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Hepatitis B Therapeutic Drug Introduction
11.1.4 GlaxoSmithKline Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.1.5 GlaxoSmithKline Recent Development
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Detail
11.2.2 Bristol-Myers Squibb Business Overview
11.2.3 Bristol-Myers Squibb Hepatitis B Therapeutic Drug Introduction
11.2.4 Bristol-Myers Squibb Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.2.5 Bristol-Myers Squibb Recent Development
11.3 Mitsubishi Tanabe Pharma
11.3.1 Mitsubishi Tanabe Pharma Company Detail
11.3.2 Mitsubishi Tanabe Pharma Business Overview
11.3.3 Mitsubishi Tanabe Pharma Hepatitis B Therapeutic Drug Introduction
11.3.4 Mitsubishi Tanabe Pharma Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.3.5 Mitsubishi Tanabe Pharma Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Hepatitis B Therapeutic Drug Introduction
11.4.4 Johnson & Johnson Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Hepatitis B Therapeutic Drug Introduction
11.5.4 Roche Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.5.5 Roche Recent Development
11.6 Gilead Sciences
11.6.1 Gilead Sciences Company Detail
11.6.2 Gilead Sciences Business Overview
11.6.3 Gilead Sciences Hepatitis B Therapeutic Drug Introduction
11.6.4 Gilead Sciences Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.6.5 Gilead Sciences Recent Development
11.7 Merck & Co. Inc.
11.7.1 Merck & Co. Inc. Company Detail
11.7.2 Merck & Co. Inc. Business Overview
11.7.3 Merck & Co. Inc. Hepatitis B Therapeutic Drug Introduction
11.7.4 Merck & Co. Inc. Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.7.5 Merck & Co. Inc. Recent Development
11.8 Novartis
11.8.1 Novartis Company Detail
11.8.2 Novartis Business Overview
11.8.3 Novartis Hepatitis B Therapeutic Drug Introduction
11.8.4 Novartis Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.8.5 Novartis Recent Development
11.9 AbbVie
11.9.1 AbbVie Company Detail
11.9.2 AbbVie Business Overview
11.9.3 AbbVie Hepatitis B Therapeutic Drug Introduction
11.9.4 AbbVie Revenue in Hepatitis B Therapeutic Drug Business (2019-2024)
11.9.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Hepatitis B Therapeutic Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Entecavir
Table 3. Key Players of Tenofovir
Table 4. Key Players of Lamivudine
Table 5. Key Players of Adefovir
Table 6. Key Players of Telbivudine
Table 7. Key Players of Others
Table 8. Global Hepatitis B Therapeutic Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Hepatitis B Therapeutic Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 10. Global Hepatitis B Therapeutic Drug Market Size by Region (2019-2024) & (US$ Million)
Table 11. Global Hepatitis B Therapeutic Drug Market Share by Region (2019-2024)
Table 12. Global Hepatitis B Therapeutic Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 13. Global Hepatitis B Therapeutic Drug Market Share by Region (2025-2030)
Table 14. Hepatitis B Therapeutic Drug Market Trends
Table 15. Hepatitis B Therapeutic Drug Market Drivers
Table 16. Hepatitis B Therapeutic Drug Market Challenges
Table 17. Hepatitis B Therapeutic Drug Market Restraints
Table 18. Global Hepatitis B Therapeutic Drug Revenue by Players (2019-2024) & (US$ Million)
Table 19. Global Hepatitis B Therapeutic Drug Market Share by Players (2019-2024)
Table 20. Global Top Hepatitis B Therapeutic Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis B Therapeutic Drug as of 2023)
Table 21. Ranking of Global Top Hepatitis B Therapeutic Drug Companies by Revenue (US$ Million) in 2023
Table 22. Global 5 Largest Players Market Share by Hepatitis B Therapeutic Drug Revenue (CR5 and HHI) & (2019-2024)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Hepatitis B Therapeutic Drug Product Solution and Service
Table 25. Date of Enter into Hepatitis B Therapeutic Drug Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Hepatitis B Therapeutic Drug Market Size by Type (2019-2024) & (US$ Million)
Table 28. Global Hepatitis B Therapeutic Drug Revenue Market Share by Type (2019-2024)
Table 29. Global Hepatitis B Therapeutic Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 30. Global Hepatitis B Therapeutic Drug Revenue Market Share by Type (2025-2030)
Table 31. Global Hepatitis B Therapeutic Drug Market Size by Application (2019-2024) & (US$ Million)
Table 32. Global Hepatitis B Therapeutic Drug Revenue Market Share by Application (2019-2024)
Table 33. Global Hepatitis B Therapeutic Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 34. Global Hepatitis B Therapeutic Drug Revenue Market Share by Application (2025-2030)
Table 35. North America Hepatitis B Therapeutic Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. North America Hepatitis B Therapeutic Drug Market Size by Country (2019-2024) & (US$ Million)
Table 37. North America Hepatitis B Therapeutic Drug Market Size by Country (2025-2030) & (US$ Million)
Table 38. Europe Hepatitis B Therapeutic Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. Europe Hepatitis B Therapeutic Drug Market Size by Country (2019-2024) & (US$ Million)
Table 40. Europe Hepatitis B Therapeutic Drug Market Size by Country (2025-2030) & (US$ Million)
Table 41. Asia-Pacific Hepatitis B Therapeutic Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 42. Asia-Pacific Hepatitis B Therapeutic Drug Market Size by Region (2019-2024) & (US$ Million)
Table 43. Asia-Pacific Hepatitis B Therapeutic Drug Market Size by Region (2025-2030) & (US$ Million)
Table 44. Latin America Hepatitis B Therapeutic Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Latin America Hepatitis B Therapeutic Drug Market Size by Country (2019-2024) & (US$ Million)
Table 46. Latin America Hepatitis B Therapeutic Drug Market Size by Country (2025-2030) & (US$ Million)
Table 47. Middle East & Africa Hepatitis B Therapeutic Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Middle East & Africa Hepatitis B Therapeutic Drug Market Size by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Hepatitis B Therapeutic Drug Market Size by Country (2025-2030) & (US$ Million)
Table 50. GlaxoSmithKline Company Detail
Table 51. GlaxoSmithKline Business Overview
Table 52. GlaxoSmithKline Hepatitis B Therapeutic Drug Product
Table 53. GlaxoSmithKline Revenue in Hepatitis B Therapeutic Drug Business (2019-2024) & (US$ Million)
Table 54. GlaxoSmithKline Recent Development
Table 55. Bristol-Myers Squibb Company Detail
Table 56. Bristol-Myers Squibb Business Overview
Table 57. Bristol-Myers Squibb Hepatitis B Therapeutic Drug Product
Table 58. Bristol-Myers Squibb Revenue in Hepatitis B Therapeutic Drug Business (2019-2024) & (US$ Million)
Table 59. Bristol-Myers Squibb Recent Development
Table 60. Mitsubishi Tanabe Pharma Company Detail
Table 61. Mitsubishi Tanabe Pharma Business Overview
Table 62. Mitsubishi Tanabe Pharma Hepatitis B Therapeutic Drug Product
Table 63. Mitsubishi Tanabe Pharma Revenue in Hepatitis B Therapeutic Drug Business (2019-2024) & (US$ Million)
Table 64. Mitsubishi Tanabe Pharma Recent Development
Table 65. Johnson & Johnson Company Detail
Table 66. Johnson & Johnson Business Overview
Table 67. Johnson & Johnson Hepatitis B Therapeutic Drug Product
Table 68. Johnson & Johnson Revenue in Hepatitis B Therapeutic Drug Business (2019-2024) & (US$ Million)
Table 69. Johnson & Johnson Recent Development
Table 70. Roche Company Detail
Table 71. Roche Business Overview
Table 72. Roche Hepatitis B Therapeutic Drug Product
Table 73. Roche Revenue in Hepatitis B Therapeutic Drug Business (2019-2024) & (US$ Million)
Table 74. Roche Recent Development
Table 75. Gilead Sciences Company Detail
Table 76. Gilead Sciences Business Overview
Table 77. Gilead Sciences Hepatitis B Therapeutic Drug Product
Table 78. Gilead Sciences Revenue in Hepatitis B Therapeutic Drug Business (2019-2024) & (US$ Million)
Table 79. Gilead Sciences Recent Development
Table 80. Merck & Co. Inc. Company Detail
Table 81. Merck & Co. Inc. Business Overview
Table 82. Merck & Co. Inc. Hepatitis B Therapeutic Drug Product
Table 83. Merck & Co. Inc. Revenue in Hepatitis B Therapeutic Drug Business (2019-2024) & (US$ Million)
Table 84. Merck & Co. Inc. Recent Development
Table 85. Novartis Company Detail
Table 86. Novartis Business Overview
Table 87. Novartis Hepatitis B Therapeutic Drug Product
Table 88. Novartis Revenue in Hepatitis B Therapeutic Drug Business (2019-2024) & (US$ Million)
Table 89. Novartis Recent Development
Table 90. AbbVie Company Detail
Table 91. AbbVie Business Overview
Table 92. AbbVie Hepatitis B Therapeutic Drug Product
Table 93. AbbVie Revenue in Hepatitis B Therapeutic Drug Business (2019-2024) & (US$ Million)
Table 94. AbbVie Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hepatitis B Therapeutic Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Hepatitis B Therapeutic Drug Market Share by Type: 2023 VS 2030
Figure 3. Entecavir Features
Figure 4. Tenofovir Features
Figure 5. Lamivudine Features
Figure 6. Adefovir Features
Figure 7. Telbivudine Features
Figure 8. Others Features
Figure 9. Global Hepatitis B Therapeutic Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Hepatitis B Therapeutic Drug Market Share by Application: 2023 VS 2030
Figure 11. Hospital Pharmacies Case Studies
Figure 12. Retail Pharmacies & Drug Stores Case Studies
Figure 13. Others Case Studies
Figure 14. Hepatitis B Therapeutic Drug Report Years Considered
Figure 15. Global Hepatitis B Therapeutic Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Hepatitis B Therapeutic Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Hepatitis B Therapeutic Drug Market Share by Region: 2023 VS 2030
Figure 18. Global Hepatitis B Therapeutic Drug Market Share by Players in 2023
Figure 19. Global Top Hepatitis B Therapeutic Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis B Therapeutic Drug as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Hepatitis B Therapeutic Drug Revenue in 2023
Figure 21. North America Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Hepatitis B Therapeutic Drug Market Share by Country (2019-2030)
Figure 23. United States Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Hepatitis B Therapeutic Drug Market Share by Country (2019-2030)
Figure 27. Germany Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Hepatitis B Therapeutic Drug Market Share by Region (2019-2030)
Figure 35. China Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Hepatitis B Therapeutic Drug Market Share by Country (2019-2030)
Figure 43. Mexico Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Hepatitis B Therapeutic Drug Market Share by Country (2019-2030)
Figure 47. Turkey Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Hepatitis B Therapeutic Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. GlaxoSmithKline Revenue Growth Rate in Hepatitis B Therapeutic Drug Business (2019-2024)
Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Hepatitis B Therapeutic Drug Business (2019-2024)
Figure 51. Mitsubishi Tanabe Pharma Revenue Growth Rate in Hepatitis B Therapeutic Drug Business (2019-2024)
Figure 52. Johnson & Johnson Revenue Growth Rate in Hepatitis B Therapeutic Drug Business (2019-2024)
Figure 53. Roche Revenue Growth Rate in Hepatitis B Therapeutic Drug Business (2019-2024)
Figure 54. Gilead Sciences Revenue Growth Rate in Hepatitis B Therapeutic Drug Business (2019-2024)
Figure 55. Merck & Co. Inc. Revenue Growth Rate in Hepatitis B Therapeutic Drug Business (2019-2024)
Figure 56. Novartis Revenue Growth Rate in Hepatitis B Therapeutic Drug Business (2019-2024)
Figure 57. AbbVie Revenue Growth Rate in Hepatitis B Therapeutic Drug Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
